Agilent Technologies Singapore (International) Pte. Ltd. - Advanced Manufacturing

Company Profile (Updated April 2026)

Agilent Technologies Singapore (International) Pte. Ltd. is a Singapore-incorporated subsidiary of Agilent Technologies Inc. (NYSE: A), a global leader in life Sciences, diagnostics, and applied chemical markets. The company was established on May 3, 2018 and operates from its primary location at 1 Yishun Avenue 7, Singapore 768923, within the surgical and medical instrument manufacturing sector.

As part of Agilent's global manufacturing network of 28 facilities, the Singapore entity plays a strategic role in producing sophisticated analytical instruments for worldwide distribution. The facility maintains a compact operational structure and focuses on high-value precision manufacturing of life sciences instrumentation, serving as a critical node in Agilent's integrated global supply chain.

Corporate Structure & Governance

Legal Entity: Agilent Technologies Singapore (International) Pte. Ltd.
   Incorporation Date: May 3, 2018
   Registered Office Address: 80 Robinson Road, #02-00, Singapore 068898
   Operating/TrADINg Address: 1 Yishun Avenue 7, Singapore 768923
   Company Type: Private Company Limited by Shares
   Industry: Surgical and Medical Instrument Manufacturing / Engineering and Scientific Instruments
   Operating Status: Active
   Parent Company: Agilent Technologies Inc. (NYSE: A)
   Global Parent Revenue: $6.95 billion (FY2025, ended October 31, 2025); $1.80 billion (Q1 2026, ended January 31, 2026)
   Global Parent Employees: ~18,000 worldwide

The entity operates as a specialized manufacturing and fulfillment node within Agilent's integrated global supply chain, coordinating with parent company operations across Americas, Europe, and Asia-Pacific regions.

Manufacturing Operations & Product Portfolio

Liquid Chromatography/Mass Spectrometry (LC/MS) Manufacturing

The Singapore facility serves as a global manufacturing center for Agilent's advanced LC/MS instruments, which are essential analytical tools used across pharmaceutical, biotechnology, food safety, environmental, chemical, and academic research sectors. The facility produces:

- Agilent 6100 Series: Single-Quadrupole LC/MS systems

- Agilent 6200 Series: Accurate-Mass Time-of-Flight LC/MS systems

- Agilent 6400 Series: Triple Quadrupole LC/MS systems

- Agilent 6500 Series: Accurate-Mass Quadrupole Time-of-Flight LC/MS systems

These sophisticated instruments support applications ranging from basic research through manufacturing quality control in pharmaceutical and biopharmaceutical industries.

Supply Chain and Order Fulfillment

The facility houses the Agilent Life Sciences Group Order Fulfillment Center, which manages comprehensive supply-chain functions including planning, procurement, value-added engineering, and logistics. This integrated approach ensures efficient delivery of configurable solutions to customers worldwide while maintaining Agilent's quality standards.

Technological Innovation & Smart Manufacturing

Fourth Industrial Revolution (4IR) Leadership: The Singapore facility has been recognized as a model of smart manufacturing through the deployment of:

- Artificial Intelligence and Machine Learning: Optimizing production processes and predictive maintenance

- Advanced Robotics: Automating precision assembly and quality control

- Data Analytics: Real-time monitoring and optimization of manufacturing operations

- Industrial Internet of Things (IIoT): Connected systems enabling seamless operational coordination

These technologies have enabled the facility to achieve significant productivity gains while supporting Agilent's corporate goal of net-zero greenhouse gas emissions by 2050.

Parent Company Performance & Outlook (2026)

Agilent Technologies Inc. Global Results:

- FY2025 Revenue: $6.95 billion (+6.7% reported growth; +4.9% core growth), ended October 31, 2025

- Q1 2026 Revenue: $1.80 billion (+7.0% reported growth; +4.4% core growth), ended January 31, 2026

- Q1 2026 Segment Performance: Life Sciences and Diagnostics Markets Group (LDG) revenue $679 million (+5% reported); Agilent CrossLab Group (ACG) revenue $758 million (+9% reported)

- CEO: Padraig McDonnell (appointed February 2024)

FY2026 Full-Year Guidance (Updated February 2026): Agilent expects revenue in the range of $7.30 billion to $7.50 billion, representing 5.5-7.5% reported growth and 4-6% core growth. Non-GAAP earnings per share guidance raised to $5.90 to $6.04. The company anticipates growth across all end markets, with continued strength in biopharma and applied markets driving performance throughout the fiscal year.

Strategic Importance & Regional Role

Center of Excellence in Asia: Over the past decade, Agilent has established Singapore as its Centre of Excellence in Asia for key business activities including:

- Intellectual property (IP) management

- Sales and marketing coordination

- Advanced manufacturing of life science instruments for global markets

The strategic location provides Agilent with enhanced access to the growing life sciences instrument market in Asia-Pacific, while leveraging Singapore's strong precision engineering supplier base, skilled technical professionals, and excellent logistics connectivity.

Contact Information

Singapore Operations

Address: 1 Yishun Avenue 7, Singapore 768923
   Email: ccc-smt@agilent.com
   Phone: 1800 276 2622 (Singapore Toll-Free) / +65 6377 1688
   Fax: +65 6270 8372

Registered Office

Address: 80 Robinson Road, #02-00, Singapore 068898

Global Headquarters (Parent Company)

Company: Agilent Technologies Inc.
   Address: 5301 Stevens Creek Blvd, Santa Clara, CA 95051, USA
   Investor Relations: investors.agilent.com
   Website: www.agilent.com

Keywords: Agilent Technologies Singapore,Agilent Singapore International,安捷伦科技新加坡,Agilent Singapore,Yishun Avenue 7,LC/MS manufacturing,life sciences instruments,WEF Global Lighthouse,Fourth Industrial Revolution,smart manufacturing,agilent technologies,singapore manufacturing,FY2025,6.95 billion,Q1 2026,1.80 billion,Padraig McDonnell,net zero 2050,NYSE A